| Concomitant reduction of low-density lipoprotein-cholesterol and biomarkers of inflammation with low-dose simvastatin therapy in patients with type 1 diabetes. | |
| | |
MedLine Citation:
|
PMID: 17519305 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
CONTEXT: Cardiovascular disease is a major cause of mortality in type 1 diabetes (TIDM). TIDM is a proinflammatory state. Whereas there is consensus on lipid management in type 2 diabetes, there is a lack of data in type 1 diabetes. In addition to benefits on the lipid profile, statin therapy is antiinflammatory. OBJECTIVE: There are scant data on statin therapy in T1DM. Thus, we tested the effect of simvastatin, compared with placebo, on biomarkers of inflammation and monocyte function in TIDM patients. DESIGN: This was a double-blind, randomized, placebo-controlled study of T1DM patients, randomized to placebo or simvastatin, 20 mg/d for 3 months. SETTING: The study was conducted at the University of California, Davis, Medical Center. PARTICIPANTS: Participants included patients with T1DM. METHODS AND RESULTS: Analytes measured at baseline and 3 months included liver function tests, creatinine, hemoglobin AIC, high-sensitivity C-reactive protein, soluble CD40 ligand, monocyte O(2)(-), cytokines, nuclear factor-kappaB. Simvastatin therapy resulted in significant reduction in low-density lipoprotein and non-high-density lipoprotein cholesterol, high-sensitivity C-reactive protein (18% reduction, P < 0.001) and soluble CD40 ligand (22% reduction, P < 0.05), compared with placebo. Simvastatin therapy significantly inhibited lipopolysaccharide-activated monocyte release of O(2)(-) (P < 0.0005), IL-8 (P < 0.03), and TNF (P < 0.02). Simvastatin therapy significantly inhibited monocyte IL-6 release, compared with baseline (P = 0.02). Simvastatin therapy also significantly reduced monocytic nuclear factor-kappaB p65 activity, compared with placebo (P < 0.01). CONCLUSIONS: This study demonstrates that simvastatin (20 mg/d) is safe in T1DM patients and has concomitant benefits on the lipid profile and biomarkers of inflammation. These novel findings could have implications for developing policy guidelines for statin therapy in forestalling vascular complications in young T1DM. |
| | |
Authors:
|
Ishwarlal Jialal; Eric Miguelino; Steven C Griffen; Sridevi Devaraj |
Related Documents
:
|
9816555 - Attitude changes of general practitioners towards lowering ldl cholesterol. 11182215 - Decrease in carotid intima media thickness after 1 year of cilostazol treatment in pati... 18042505 - Effectiveness and tolerability of oral administration of low-dose salmon oil to hiv pat... 18467115 - Raloxifene has favourable effects on metabolic parameters but has no effect on left ven... 8769455 - Partial denervation for persistent neuroma pain around the knee. 6945795 - Chronic myeloid leukemia in myasthenia gravis after long-term treatment with 6-mercapto... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural Date: 2007-05-22 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 92 ISSN: 0021-972X ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-08-08 Completed Date: 2007-09-17 Revised Date: 2013-01-23 |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 3136-40 Citation Subset: AIM; IM |
Affiliation:
|
Laboratory for Atherosclerosis and Metabolic Research, University of California, Davis, Medical Center, Sacramento, California 95817, USA. ishwarlal.jialal@ucdmc.ucdavis.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Biological Markers Cholesterol / blood Cholesterol, LDL / blood* Cytokines / blood Diabetes Mellitus, Type 1 / blood* Double-Blind Method Female Hemoglobin A, Glycosylated / metabolism Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use* Inflammation / metabolism* Lipoproteins, LDL / blood* Male Monocytes / drug effects, metabolism, physiology Simvastatin / therapeutic use* Triglycerides / blood |
| Grant Support | |
ID/Acronym/Agency:
|
K24 AT000596-09/AT/NCCAM NIH HHS; K24 AT000596-10/AT/NCCAM NIH HHS; K24 AT00596/AT/NCCAM NIH HHS; R21 DK069801/DK/NIDDK NIH HHS; R21 DK069801-02/DK/NIDDK NIH HHS; R21DK69801/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Cholesterol, LDL; 0/Cytokines; 0/Hemoglobin A, Glycosylated; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipoproteins, LDL; 0/Triglycerides; 57-88-5/Cholesterol; 79902-63-9/Simvastatin |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ovarian androgen production in postmenopausal women.
Next Document: Hormonal and nutritional effects on cardiovascular risk markers in young women.